Lexaria Bioscience : Corporate Presentation

Lexaria Bioscience Corp.

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX

Drug Delivery Platform Innovator

Investor Presentation

January 2021

LexariaBioscience.com

1

Disclaimer

This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, research and development, alternative health projects or products, clinical trials, regulatory approvals, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions that are forward- looking statements. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements including, without limitation, foreign exchange and other financial markets; changes of the interest rates on borrowings; whether or not the Company will be successful in executing its business plan in whole or in part; hedging activities; changes in commodity prices; changes in the marketing or capital project expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Lexaria Bioscience Corp. operates. These and other risks and uncertainties are more fully described in our periodic reports and other disclosure documents filed by Lexaria Bioscience Corp. from time to time with regulatory authorities available on SEDAR at www.sedar.comand on EDGAR at www.sec.gov, and the reader is encouraged to review these documents. Planned dates stated herein are estimates only, based on best information available. Dates are not assured and are subject to revision without notice. The Company assumes no obligation, except as required by law, to update any forward-looking statement, whether as a result of new information, future events or otherwise. This presentation is not an offer to sell or a solicitation of an offer to buy securities of Lexaria Bioscience Corp. It is a short summary of certain information for introductory purposes only and is not to be relied upon for investment purposes.

No statement within has been evaluated by the Food and Drug Administration, and no product or service is intended to diagnose, treat, cure or prevent any disease.

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX

2

Lexaria Bioscience - Corporate Highlights

• Disruptive, patented technology - designed for fast acting, less expensive & more effective oral drug delivery:
• • Potential applications in: Antivirals (COVID-19, HIV and other infectious diseases); Oral Nicotine; NSAIDs (Ibuprofen, Aspirin); Cannabinoids; Fat-Soluble Vitamins (A,D,E,K); PDE5 Inhibitors (Viagra, Cialis); Hormones (Estrogen, Testosterone)
• DehydraTECH™ Technology Platform:
• • Patented formulation and dehydration processing method changes how the body senses and absorbs drugs orally*
  • Clinically demonstrated (see:https://www.ncbi.nlm.nih.gov/pubmed/31512143orhttps://rdcu.be/bQZZi)
  • Designed for faster onset/offset and higher bioavailability in capsules, foods, liquids, mixable powders, etc.
  • 18 patents granted (>50 patent applications pending) covering method-of-use,composition-of-matter and medical treatment claims
• Programs commenced to evaluate delivery effectiveness with cannabidiol (CBD) for hypertension and antiviral applications for SARS diseases (incl. COVID-19) and other infectious diseases
• Oral nicotine products to disrupt the US$814 billion** global nicotine market
• • Altria Group international license rights for undisclosed royalty
  • Research collaboration under way with British American Tobacco
  • Also in discussions with other tobacco/pharma companies

Focused on commercialization through partnerships and licensing

*Based on subjective and objective clinical testing in 82 human volunteers with CBD, THC and nicotine formulations, in vivo animal testing in 316 rodents with CBD and nicotine formulations and hundreds of thousands of commercial product servings of CBD and THC formulations by Lexaria's licensing partners.

**https://www.bat.com/group/sites/UK__9D9KCY.nsf/vwPagesWebLive/DO9DCKFM3

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX

Key Executives, Directors and Advisors

Chris Bunka Chairman & CEO

• Serial entrepreneur involved in several private and public companies since the late 1980's
• Extensive experience in the capital markets, corporate governance, M&A and finance
• Named inventor on multiple patent innovations

John Docherty, M.Sc. President

• Specialist in development of drug delivery technologies
• Former President and COO of Helix BioPharma Corp. (TSX: HBP)
• Named inventor on multiple issued and pending patents
• Pharmacologist and toxicologist

Gregg Smith Strategic Advisor

• Founder and Private Investor, Evolution VC Partners
• Early JUUL Labs, Pax Labs, Beyond Meat investor
• Member of Sand Hill Angels - active Silicon Valley angel investment group
• Previous Investment Banking roles with Cowen and Company, BOA Merrill Lynch

Dr. Philip Ainslie Scientific & Medical Advisor

• Co-Directorfor the Centre for Heart, Lung and Vascular Health, Canada
• Research Chair in Cerebrovascular Physiology and Professor, School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia

Brian Quigley Director

• Co-Founderof cannabis consulting firm, Green Sky Strategy
• 16 years at Altria Group; with seven of those years spent as president and CEO for U.S. Smokeless Tobacco and Nu-Mark

Jamieson Bondarenko, CFA, CMT Capital Markets Advisor

• Capital Markets Advisor to MustGrow Biologics
• Chairman of BriaCell Therapeutics
• Previous Equity Capital Markets roles with Eight Capital, Dundee Securities, HSBC

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX

4

Patented DehydraTECH™ Drug Delivery

			*
P Speeds up onset	P Increases bioavailability	P Improves palatability

1	Combine "API" with	2	Apply to food / carrier	3	Perform dehydration
	Fatty Acid Oil		particles		synthesis procedure

API	Fatty Acid	Sorbitol, Gum Arabic, etc.
(e.g., LCFA)

• Render as powder or liquid for use in desired final form factor

*Based on subjective and objective clinical testing in 82 human volunteers with CBD, THC and nicotine formulations, in vivo animal testing in 316 rodents with CBD and nicotine formulations and hundreds of thousands of commercial product servings of CBD

and THC formulations by Lexaria's licensing partners.
API = Active Pharmaceutical Ingredient	NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX	5
LCFA = Long Chain Fatty Acid (e.g., oleic acid rich sunflower oil)

ü Close collaboration with largest R&D organization in Canada, the National Research Council, since January 2017

ü Thoroughly evaluated through:

ü Nuclear Magnetic Resonance (NMR);

ü Fourier Transform Infrared Spectroscopy (FTIR);

ü Liquid Chromatography-HighResolution Mass Spectroscopy (LC-HRMS);

ü Dynamic Light Scattering (DLS); and Zeta Potential analysis

ü NMR molecular characterization suggests DehyrdraTECH does notchange the chemical structure of the API it delivers, allowing some reliance on original API safety characterization.

ü DehydraTECH shown to reduce particle size through a patented, novel method4

How Does DehydraTECH™ Work?

Fatty acids are believed to

block and shunt bound APIs away from bitter taste receptors1

Lipids enable gastric protection and rapid passage2

Small intestine quickly absorbs

LCFAs into lymphatics

(bypassing first pass liver effect) and MCFAs via the liver3

API = Active Pharmaceutical Ingredient LCFA = Long Chain Fatty Acid

MCFA - Medium Chain Fatty Acid

1Coupland & Hayes (2014). Pharm Res. Nov 31(11); 2921-29392Soehngen et al., (1998). Arthritis & Rheumatism. Vol 31, No. 3.

3Iqbal & Hussain (2009). Am J Physiol Endocrinol Metab. Jun;296(6);E1184-94

4Based on dynamic light scattering particle size evaluation studies conducted by Canada's National Research Council as announced July 16, 2020.

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX

6

DehydraTECH™ - Patented Technology Potential Benefits

Masks unwanted	Improves speed of	Increases	Increases brain	Reduces Drug
taste*	onset	bioavailability	absorption	Administration Costs

Eliminates the	Effects are felt in	Much more	Animal testing	Higher ratio of
need for sugar-	minutes**	effective at	suggests up to 19x	drug delivery
filled edibles		delivering drug	improvement****	expected to lower
		into		overall drug costs
		bloodstream***

Patented drug delivery technology may improve oral

administration of Active Pharmaceutical Ingredients (APIs)

*Based on subjective clinical testing in 30 human volunteers with CBD, THC and nicotine formulations and hundreds of thousands of commercial product servings of CBD and THC formulations by Lexaria's licensing partners. **Based on subjective clinical testing in 70 human volunteers with CBD, THC and nicotine formulations and hundreds of thousands of commercial product servings of CBD and THC formulations by Lexaria's licensing partners.

***Based on objective clinical testing in 12 human volunteers with CBD formulations, and in vivo animal testing in 316 rodents with CBD and nicotine formulations

****www.lexariabioscience.com/news/lexaria-bioscience-announces-new-dehydrateh-innovation-files-new-patents/

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX

7

Growing Markets

Global Controlled Release Drug Delivery Market	Global Drug Delivery Systems Market
$69.8B	$900B

7.8% $37.8B

CAGR

2019 2027

Pharmaceutical companies are pro-active with advances in technology and are continuously investing in improving drug delivery systems.

6.9% $510B

CAGR

2017 2025

Becton, Dickinson & Company, Johnson and Johnson Services, Inc., AstraZeneca plc., Baxter International, Inc., Novartis AG, F. Hoffman-La Roche, GlaxoSmithKline plc, and Antares Pharma, Inc. are some of the renowned companies in the global drug delivery systems market

https://www.grandviewresearch.com/industry-analysis/controlled-	https://www.transparencymarketresearch.com/drug-delivery-
release-drug-delivery-market	NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX systems-market.html	8

Major Product Development Pipeline Opportunities

POC = Proof-of-concept

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX

9

DehydraTECHTM for Cannabinoids - Faster and More Effective Delivery

Methods of Cannabinoid Consumption
1. Inhalation	CASE STUDY: TurboCBD™ - Lexaria's Oral CBD Product
• High bioavailability (~27%1), harmful to Lungs	• 90mg DehydraTECH dose vs. Competitor 100mg dose
2. Sub-lingual (under tongue)
• Competitor delivers virtually zero CBD at 30 minutes
• Medium bioavailability (~13%2), foul taste	• Lexaria quicker "on" and quicker "off"

3. Oral - Gastrointestinal Tract

• Low bioavailability (~6%1), sugar filled to mask taste

DehydraTECHTM (Oral Technology)

Transforms the way cannabinoids enter the bloodstream through the gastrointestinal tract

• Fast Acting
• Improved Taste
• Increased Bioavailability
• Improved Blood Brain Barrier Penetration3

Plasma concentration (ng/mL)

D 90mg	PTL101 - 100mg	Faster onset
and offset;
60
	higher peak
50		concentration

40

30

20

10

0
0	30	60	90	120	150	180	210	240	300	360	420	480
					Time (min)

1Clin Chem. 2011 Jan; 57(1):66-75.

2Clinical Pharmacology in Drug Development 2017, 00(0) 1-8

3Based upon preclinical studies in animals

Pharmacokinetic comparison of the ingestion of DehydraTECHTM 90mg (solid black solid circles) and PhytoTech

Therapeutics' PTL101-100mg gelatin matrix capsules (dashed grey open squares) [Atsmon et al., Clinical

Pharmacology in Drug Development 2018, 7(7) 751-758].

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX

10

10

Case Study: TurboCBD™ - Clinically Demonstrated Blood/Body Response Benefits

• 2018 European human clinical study (n=12)
• Double-blind,90 mg CBD dose
• 317% more CBD delivered
  ≤ 30 min (only TurboCBD 90 > placebo; p<0.05)
• Higher CBD delivery throughout entire study
• Lower blood pressure shown vs. baseline (p < 0.05)
• Higher cerebral perfusion shown vs. baseline (p < 0.001 )

Venous plasma concentration (ng/mL)

80										Turbo 90mg
70		**		90mg
**					placebo
60

50

40

30	Ψ
Ψ
20
10	317% more
CBD delivered
	≤ 30 min.

0
0	30	60	90	120	150	180	210	240	270	300	330	360
						Time (min)

Plasma cannabidiol (CBD) concentration in venous blood over 6 hours following consumption of generic 90mg (dashed black open circles) CBD doses compared to DehydraTECHTM 90mg (solid grey solid circles) CBD doses. Standard error included for clarity. **p<0.01 TurboCBDTM 90mg > all others; Ψp<0.05 only TurboCBD 90mg > placebo. Note both generic and DehydraTECHTM are otherwise significantly greater when compared to placebo.

.

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX	11

Significant BP Reduction and Cerebral Perfusion

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX	12

Hypertension Affects More Than 1 Billion People / Year

Common side effects of current hypertension treatments include:*

• Potassium loss
• Respiratory effects
• Dizziness and weakness
• Reduced kidney function

Lexaria is researching CBD-based treatments that may have fewer side effects:

• Q1, 2020: Double-blinded, placebo controlled cross-over pilot study (300 mg DehydraTECH CBD) planned for Q1, 2021 to confirm and expand on results of Lexaria's 2018 human clinical pilot study (hospital ethics board approvals granted; study preparations underway)
• Intended to compliment Lexaria's 2018 study in which a single 90 mg dose of Lexaria's TurboCBD provided evidence of significant blood pressure reduction

• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863783/
• wwww.rxlist.com/high_blood_pressure_hypertension_medications/drug-class.htm

**https://www.who.int/news-room/fact-sheets/detail/hypertension

***https://www.biospace.com/article/antihypertensive-drugs-market-rising-global-burden-of-hypertension-provides-impetus-for-development-of-new-drugs/

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX

1.1 billion**

affected globally

20%**

Have it under control

$27.8 billion ***

Antihypertensive products market

13

Revenue Generation Underway and Growing in Cannabinoid Sector

• Wholly-ownedsubsidiary Lexaria Hemp Corp. generates revenues from DehydraTECH-enabled CBD powders via its licensees and fee-for-service clientele;
• • Lexaria announced that it had received purchase-order commitments for over 8.0 million CBD servings to be processed during the Company's fiscal Q1 2021 which ended November 30, 2020;
  • Lexaria has also received verbal requests from existing licensees to prepare the Company's facilities to produce at least 56 million servings during the calendar year 2021; and
  • This compares to approximately 1.2 million CBD servings already processed in the Company's fiscal Q4 that ended August 31, 2020, and approximately 0.7 million CBD servings during the Company's fiscal Q3 that ended May 31, 2020
• Pursuant to plans for Lexaria to uplist to a national US securities exchange, Lexaria sold its non-core, non- pharmaceutical THC-related business assets for gross proceeds of $3.85 million CDN (Approx US$2.85 million).

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX

14

NICOTINE - $814 Billion Global Mega-Market

Smoking is the world's leading cause of preventable death

• Although nicotine is not a benign substance, it is the burning of tobacco and other substances inhaled through smoking that causes cancer, heart disease and bronchitis.
• Combustion of tobacco creates >7,000 chemicals (including tar, ammonia, carbon monoxide & arsenic); >70 of which are known cancer-causing carcinogens.
• FDA has a comprehensive regulatory plan to:
• 1. Reduce nicotine in cigarettes to non-addictive levels;
  2. Encourage new product classes that deliver nicotine without the toxic by-products of burning tobacco.

1.3 billion*

smokers globally

8 million*

deaths/year globally

$300 billion**

Smoking-related US illness costs

1,300**

deaths/day in U.S.

"Cigarettes are the only legal consumer product that, when used as intended, will kill half of all long-term users." - FDA

• * https://www.who.int/news-room/fact-sheets/detail/tobacco
• **https://www.cdc.gov/tobacco/data_statistics/fact_sheets/health_effects/tobacco_related_mortality/index.htm

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX

15

DehydraTECH Science - Oral Nicotine Delivery

April 2018; n=12 (in-vivo)

• Blood sampling T=0, 15, 30, 45, 60, 120, 240 and 480 min
• 48% improvement in peak Cmax nicotine delivery to the bloodstream relative to controls
• 1,160% faster delivery of equivalent peak Cmax quantities of nicotine to the bloodstream than achieved with controls (within 15 min vs. 2.9 hours)
• 560% higher brain levels of nicotine where nicotine effects are focused, compared to controls

August 2018; n=40 (in-vivo)

• Blood sampling T=0, 2, 4, 6, 8, 12, 15, 30, 45 and 60 min
• 90% more nicotine delivered at 10 minute mark
• 70% more nicotine delivered overall within first 15 mins of study
• 94% more nicotine delivered over the 60 min study period
• 295% higher brain levels of nicotine where nicotine effects are focused, compared to controls

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX

16

https://www.marketwatch.com/press-release/smokeless-tobacco-market-share-size-global-growth-prospects-trends-industry-analysis-key-players-and-forecast-to-2025-2020-11-05

Strategic Licensing - Oral Nicotine Delivery

Altria Group License

• January 2019: License and funding to test ingestible/oral nicotine products
• International licence rights
• Undisclosed royalty on any oral nicotine product sales utilizing DehydraTECH

Majority Interest

Minority Interest

Oral Nicotine (Non-Smoking Alternative)

• 68% of U.S. smokers wish to quit; 55% attempt & fail each year; 7.5% succeed - FDA is encouraging new product classes to improve successful quit attempts *
• Non-combustednicotine delivery represents an increasingly large fraction of global demand **
• A fast acting, high absorptionand palatableorally- ingestible nicotine product is an eloquent solution and would satiate not only the physical nicotine craving, but also the behavioral, emotional and social aspects associated with nicotine addiction

Research collaboration also in process with British American Tobaccoand discussions

underway with other Global-500 companies for DehydraTECH oral nicotine use

*https://www.cdc.gov/tobacco/data_statistics/fact_sheets/cessation/smoking-cessation-fast-facts/index.html **https://www.marketwatch.com/press-release/smokeless-tobacco-market-share-size-global-growth-prospects-trends-industry-analysis-key-players-and-forecast-to-2025-2020-11-05

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX

17

Target Infectious Disease Drug Classes - COVID-19, HIV & Other

Viral Diseases

Vaccines

Antiviral drug

market $36.1B;

expected to

grow to $44.2B

by 2026 *

Treatment		Antiviral Drugs

Antiretroviral Drugs	General Antiviral (Non-Retro)
•	Protease Inhibitors	• Nucleoside and Nucleotide Analogs
•	Fusion Inhibitors	•	Pyrimidines
•	Nucleoside, Non- Nucleoside &	•	Antisense Drugs
	Nucleotide Reverse	•	Interferon-Alpha and Combinations
	Transcriptase Inhibitors	•	Topical Immune Modulators

• Ion Channel Function Inhibitors of M2

Proteins and Neuraminidase Inhibitors

Target Diseases:

•	COVID-19	•	EBV
•	HIV	•	HEP
•	HSV	•	CMV
•	Influenza

• https://www.marketwatch.com/press-release/antiviral-drugs-market-size-growth-2020-covid-19-impact-on-healthcare-sector-share-business-regional-analysis-competitive-landscape-with-global-forecast-to-2026-2020-11-04?tesla=y

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX

18

COVID-19(SARS-CoV-2)

Present Antiviral Therapy Landscape

• Antiviral therapies are being investigated to potentially fight infection
• Oral antiviral therapies needed for mass distribution
• Many oral antiviral drugs are fat soluble and poorly absorbed, compromising potency and are exceptionally expensive, limiting access if hundreds of millions of doses are required

Lexaria's DehydraTECH - Antiviral Research

• DehydraTECH is clinically demonstrated to significantly increase bioavailability for fat soluble
• Pilot human PK study pending at a leading Canadian university (conditional hospital ethics board approval received)
• Rodent PK study completed evidencing significant enhancement in oral delivery of antiviral drugs
• Objective is to increase drug delivery orally for greater therapeutic response, tolerability and to lower cost of drugs
• Research expected to lead to expanded safety and efficacy testing in COVID-19 and other infectious disease animal models

Many oral antivirals are poorly absorbed fat soluble drugs which compromises

potency and are exceptionally expensive - limiting dosing capability

*Based on objective clinical testing in 12 human volunteers with CBD formulations, and in vivo animal testing in 316 rodents with CBD and nicotine formulations

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX

19

DehydraTECH Science - Oral Antiviral Delivery

• December 2020: Rodent PK study completed (n=40) demonstrating significant enhancement in antiviral drug delivery using DehydraTECH;
• Two drugs studied (darunavir and efavirenz) from representative classes of antiviral compounds under investigation today for SARS-CoV-2/COVID-19 therapy (i.e., protease inhibitors and reverse transcriptase inhibitors), and in use for treatment of HIV/AIDS;
• More research planned for 2021 to expand upon these findings with additional antiviral drugs that are being investigated specifically for SARS- CoV-2/COVID-19; HIV/AIDS, and other viral disease.

AUC = Area Under the Curve; i.e. total drug absorption

AUClast = Measured AUC over 24 hr study duration

AUC∞ = Theoretical extrapolated maximum AUC beyond 24 hr study duration

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX

20

Corporate and Financial Information

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX

Shares Outstanding	5.1 million
Fully Diluted	8 million
Share Price	US $4.34
Insider Ownership	12.6%
Average Volume	480,000 (5-day to Jan 20)
Market Cap	US $22.6 million
Last Financing (January 2021)	US $11,000,000 (@ US$5.25/unit)

www.LexariaBioscience.com

Product Licensing & Investor Inquiries:[e-mail]

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX *as of 01/19/2021, source Nasdaq

21

Investment Catalysts/Highlights

• Disruptive drug delivery technology with multiple opportunities for success in antivirals, nicotine, cannabinoids, other APIs;
• Investigation planned or underway with CBD for hypertension, antivirals for COVID-19 and other infectious diseases, and for nicotine;
• Rapidly growing revenue-generation for DehydraTECH-enabled CBD powders;
• Additional DehydraTECH transactions expected through 2021;
• Uplist to Nasdaq Capital Markets completed in January, 2021.

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX

22

Lexaria Bioscience Corp.

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX

Drug Delivery Platform Innovator

866.221.3341

CONTACT: [e-mail] LexariaBioscience.com

23

Scientific Appendix

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX	24
	24

Example Nicotine Blood Absorption Data

	DehydraTECH	Control	% Improvement	p Value
	Formulation	Formulation
	(ng/mL)	(ng/mL)
2 minutes	56.68	105.57	-46.32	0.260114297
4 minutes	124.55	74.63	66.88	0.171769198
6 minutes	124.04	92.12	34.64	0.241171951
8 minutes	230.02	119.22	92.94	0.102332181
10 minutes	254.64	133.89	90.19	0.043918813
12 minutes	278.99	147.94	88.58	0.029947174
15 minutes	307.68	150.09	105.00	0.006564706
30 minutes	303.13	148.68	103.88	0.002363596
45 minutes	300.43	155.54	93.15	0.003034948
60 minutes	394.23	220.16	79.07	0.025735488
Peak Nicotine Blood Level 0-60 min (ng/mL)	394.23	220.16	79.07	0.025735488
Total Nicotine Absorption (i.e., AUC) 0-60 min (hr·ng/mL)	266.48	136.75	94.87	0.008632357

NOTE: No AEs reported.

p Value < 0.05 signifies statistical significance

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX

25

Nicotine Brain Tissue PK Data Highlighted

17LEXAP1 - Study of 12 lab rats with Brain Testing at 24 hours

April 2018

Test	Control Formulation	Lexaria Formulation	% Improvement
	(10 mg/Kg)	(10 mg/Kg)
Maximum Brain Concentration	51.8 ± 30.4	290 ± 197	560%
(Cmax; ng/g)

	Test	Control Formulation	Lexaria Formulation	% Improvement
		(10 mg/Kg)	(10 mg/Kg)
18LEXAP1 - Study of 40 lab rats	Maximum Brain Concentration	427 ± 66.5	1,260 ± 200
(Cmax; ng/g)	295%
with Brain Testing at 1, 4, 8 and
Time to Cmax	4 hours	1 hour	400%
24 hours
Total Quantity in Brain Tissue			221%
August 2018	5,881 ± 538	12,999 ± 1252
	(AUC; hr⋅ng/g)

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX

26

Nicotine NMR Analyses (T=0)

• No chemical shift apparent ruling out covalent bonded new chemical compound

Nicotine

Polacrilex infused mannitol (0 day)

Fatty acid oil signals

Polacrilex standard

Fatty acid oil

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX

27

2018 TurboCBD™ Clinical Study

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX

28

DehydraTECH Enhancement Underway

19LEXAP1 (05/19) Design:

• DehydraTECH CBD (with & without an intestinal absorption "enhancement" ingredient incorporation) vs. MCT-based CBD positive control
• Enhancement Ingredient is on FDA GRAS List
• 25 mg/Kg (oral gavage)
• Standard DehydraTECH formulation: CBD + sunflower oil + infusion substrate
• Enhanced DehydraTECH formulation: CBD + sunflower oil + infusion substrate + "enhancement" ingredient
• MCT formulation: CBD + MCT oil + infusion substrate
• 30 male Sprague Dawley (SD) rats (3 groups of 10)
• Jugular vein cannulation for blood collection
• Blood sampling T=0, 2, 4, 6, 8, 10, 12, 15, 30, 45 and 60 min

ng/mL

CBD Absorption (ng/mL) in SD Rats @ 25 mg/Kg (n=10/group)

250

200

150

100

50

0

0	0.033	0.067	0.1	0.13	0.2	0.25	0.5	0.75	1
				hours
		MCT	DehydraTECH		DehydraTECH-Enhanced

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX

29

Thank you

NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX	30
	30